Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

33%

Ph early_phase_1

17%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 4Post-market surveillance

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Other(1)

Detailed Status

Completed5

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 42 (40.0%)

Trials by Status

completed583%

unknown117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_4

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

NCT03816306

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT04649229Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed

NCT03744975Phase 2

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Completed

NCT04113109Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed

NCT03928158Phase 2

LCZ696 in Advanced LV Hypertrophy and HFpEF

Completed

NCT03816306

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

Completed

NCT03771729Early Phase 1

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure

Unknown

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6